Antioxidant potential of propylthiouracil in patients with psoriasis.
OBJECTIVE
There is growing evidence supporting the reactive oxygen species (ROS) in the pathogenesis of psoriasis. Propylthiouracil(PTU), an antithyroid drug, has been shown to have beneficial effects on psoriasis. The aim of this study was to investigate both disturbances in oxidant/antioxidant system in psoriasis and whether PTU, shown to have immunomodulatory effects and antioxidant potential, has effects on oxidant/antioxidant system and clinical improvement in psoriatics.


METHODS
Malondialdehyde (MDA), end product of lipid peroxidation, superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and antioxidant enzymes were measured in plasma, erythrocytes and skin biopsies of psoriatics who were resistant to conventional therapy before and after 8 weeks of oral treatment with PTU (300 mg/day) or PTU/thyroxine (25 microg/day- to prevent possible hypothyroidism). The same parameters were also studied in healthy controls. Psoriasis Area and Severity Index (PASI) scores were used to evaluate the severity of the disease, and routine analyses and thyroid function tests were measured during the study.


RESULTS
Increased baseline MDA in all samples were found to be lower. In addition baseline SOD and GSH-Px in skin and erythrocytes were also lower. The increased plasma SOD levels in skin and erythrocytes of the study groups was found to be higher and lower,respectively in all patients after the treatment. No tissue parameters or erythrocyte GSH-Px were different from control levels at the end of the study. Significant clinical improvement and decreased PASI scores were observed in all patients. Post treatment TSH levels were higher in all patients, but these levels were within the reference range and none had clinical hypothyroidism.


CONCLUSIONS
These findings may provide some evidence for a potential role of increased lipid peroxidation and decreased antioxidant activity in psoriasis. PTU may be considered as treatment model in psoriasis, in particular for resistant cases, because of its antioxidant potential, and also antiproliferative and immunomodulatory effects.
Utaş
Serap
S
Erciyes University, School of Medicine, Department of Dermatology. sutas@erciyes.edu.tr
Köse
Kader
K
Yazici
Cevad
C
Akdaş
Ahmet
A
Keleştimur
Fahrettin
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D013956:Antithyroid Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood / Q000378:metabolism; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000032:analysis / Q000097:blood; D008875:Middle Aged; D016877:Oxidants / Q000032:analysis / Q000378:metabolism; D011441:Propylthiouracil / Q000494:pharmacology* / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D013482:Superoxide Dismutase / Q000097:blood / Q000378:metabolism; D013974:Thyroxine / Q000494:pharmacology / Q000627:therapeutic use
D000975:Antioxidants; D013956:Antithyroid Agents; D016877:Oxidants; D008315:Malondialdehyde; D011441:Propylthiouracil; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D013974:Thyroxine